On 23 September 2026, Mega Genomics Limited repurchased 84,400 ordinary shares on the Hong Kong Stock Exchange at prices ranging between HKD 6.905 and HKD 7.20 per share, spending a total of HKD 0.60 million. The repurchased shares are being held as treasury stock.

Following the transaction, issued shares outstanding (excluding treasury shares) declined to 222.60 million, while treasury shares increased to 1.70 million. The company’s total issued share count remains unchanged at 224.30 million.

The buyback represents 0.0379 % of the company’s issued shares immediately prior to the transaction. Under the buyback mandate approved on 21 May 2026, Mega Genomics is authorised to repurchase up to 22.43 million shares; cumulative repurchases under this mandate now stand at 1.70 million shares, equivalent to 0.76 % of the issued share base on the mandate date.

In accordance with Hong Kong listing rules, Mega Genomics is subject to a moratorium on issuing new shares or disposing of treasury shares until 23 October 2026.